1/ Last year, we launched @SocialCapital Emerging Managers, a program designed for investment professionals looking to accelerate their careers without the typical years of waiting it takes to be allocated your own portfolio at traditional funds.
2/ We hired 11 managers, initially staking them with $4M each. They managed their own books, while also working on investments and other projects. After reviewing year-end performance, we have allocated additional capital for year 2 of the cohort.
3/ We’re excited to invite folks to apply for the EM Class of 2022. As an EM, you have access to three key benefits: (1) capital commitment of 3 years; (2) the platform/infrastructure required to trade; (3) ability to own your track record outright.
4/ In addition to U.S. equities, 2022 applicants may submit actively managed crypto strategies. Why crypto? With the emergence of Web3, we don’t want to miss exposure to one of the fastest growing asset classes. We’re open to all liquid crypto strategies focused on trading.
5/ More details attached – which also includes a summary of EM21’s Year 1 performance as well as our standard term sheet. Send all applications to EM@socialcapital.com by Feb 11.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/ As a parent, I often wonder whether there is a way for technology to be part of the solution to our country’s growing concerns around mental health.
2/ @AkiliLabs is creating a new class of medicine. Their first product is a first-of-its-kind FDA-cleared prescription video game to treat pediatric ADHD in 8-12 year-olds.
3/ Their technology targets the fronto-parietal attention control networks of the brain to improve attention function (e.g., focus, multitasking).
1/ Chronic kidney disease (CKD) is one of the most prevalent medical conditions, affecting more than 1 in 7 U.S. adults (as well as my late father). We spend up to $500B/yr to treat CKD with drugs and dialysis, which may incrementally slow down the disease but not reverse it
2/ Today we partnered with ProKidney, which is changing how we treat CKD. Their clinical data shows its treatment can not only significantly slow the onset of CKD compared to existing therapies, but even REVERSE the loss of kidney function, a first for CKD patients
3/ By taking ProKidney public, they will have the capital to continue Phase 3 clinical trials which have already commenced this month. We are excited to work with a company that has the opportunity to change how millions of people worldwide cope with this terrible disease
1/ $CLOV - upgraded MA PPO rating of 3.5 Stars (vs prior 3.0 Stars) - Proud of the @CloverHealth team and excited to see what the future holds 💪
2/ Shows CLOVs ability to execute and validates their wide-open network approach to access a larger TAM compared with narrow-network plans offered by competitors
3/ Around 50% of $CLOV's membership who self-identify are those of minority background vs only 34% average for the industry
1/ People misunderstand space and its implications. Since the Apollo project, focusing on space has allowed engineers and scientists to push the boundaries of the possible.
2/ Those advances would then find their way into our day to day lives - because when things are engineered for microscopic tolerances in space, they enable seemingly magical things on earth.
3/ We are now on the verge of a global expansion of space - from pervasive internet connectivity and interplanetary travel to space tourism.
We wrapped up our climate change competition and are pleased to announce our winners.
-1k+ applications
-180 were excellent
-35+ teams interviewed
-8 proposals stood out as particularly innovative
So we have 8 winning teams vs 3 as planned, and each will receive a $25k award.